Provided by Tiger Trade Technology Pte. Ltd.

Belite Bio, Inc.

141.32
-8.9200-5.94%
Post-market: 141.320.00000.00%18:40 EST
Volume:169.96K
Turnover:24.59M
Market Cap:5.30B
PE:-73.26
High:151.16
Open:150.25
Low:140.99
Close:150.24
52wk High:161.32
52wk Low:49.00
Shares:37.51M
Float Shares:19.96M
Volume Ratio:0.59
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9290
EPS(LYR):-1.1836
ROE:-32.30%
ROA:-21.22%
PB:19.34
PE(LYR):-119.40

Loading ...

Belite Bio Inc : Benchmark Raises Target Price to $187 From $132

THOMSON REUTERS
·
Dec 03

U.S. RESEARCH ROUNDUP-Crowdstrike, CSW Industrials, Targa Resources

Reuters
·
Dec 03

Belite Bio Inc : Maxim Group Raises Target Price to $200 From $140

THOMSON REUTERS
·
Dec 03

Belite's Tinlarebant Results Boost Wall Street Confidence -- Market Talk

Dow Jones
·
Dec 03

BUZZ-U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Cloudflare, Boeing

Reuters
·
Dec 02

BUZZ-Belite Bio eyes fresh record after $350 mln equity raise

Reuters
·
Dec 02

Belite Bio Inc : Mizuho Raises to Outperform From Neutral; Raises Target Price to $194 From $105

THOMSON REUTERS
·
Dec 02

Belite Bio Prices $350 Million Equity Offering

MT Newswires Live
·
Dec 02

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

THOMSON REUTERS
·
Dec 02

Belite Bio Inc. reports nine-month 2025 general and administrative expenses of USD 25.4 million, up over 3 times

Reuters
·
Dec 02

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

GlobeNewswire
·
Dec 02

Top Midday Gainers

MT Newswires Live
·
Dec 02

Belite Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 02

BUZZ-U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources

Reuters
·
Dec 02

Sector Update: Health Care Stocks Decline Pre-Bell Monday

MT Newswires Live
·
Dec 01

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of Manufacturing Reports

MT Newswires Live
·
Dec 01

Top Premarket Gainers

MT Newswires Live
·
Dec 01

Belite Bio Says Eye Disease Treatment Trial Meets Primary Efficacy Endpoint; Shares Up Pre-Bell

MT Newswires Live
·
Dec 01

BRIEF-Belite Bio Announces Positive Topline Results From Pivotal Global, Phase 3 Dragon Trial Of Tinlarebant

Reuters
·
Dec 01

Belite Bio's drug for genetic eye disease meets main goal in late-stage trial

Reuters
·
Dec 01